Colorectal Cancer Clinical Trial
Official title:
A Randomized Trial of a Culturally-adapted Colorectal Cancer Screening Decision Aid Designed for American Indians
| Verified date | December 2021 |
| Source | UNC Lineberger Comprehensive Cancer Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Experts note that in order to continue reducing the US cancer burden, it is critical that investigators "more completely apply discoveries in cancer prevention we have already made." Thus, it is important to research strategies that aim to improve application of effective colorectal cancer (CRC) prevention and screening tests among underserved populations like American Indians (AI).CRC is the 2nd leading cause of cancer death among AI; yet, one of the most preventable and treatable cancers when detected early. Increased use of recommended CRC screening tests among men and women ages 50-75 have contributed to nearly 50% declines in US CRC mortality since 1990. However, recent evidence indicates AI have not observed equitable improvements. The investigators propose to build upon our experience addressing CRC screening in underserved populations and strong partnerships with North Carolina tribal partners to gain new insight about a patient-centered, culturally appropriate strategy to increase AI CRC screening.
| Status | Completed |
| Enrollment | 128 |
| Est. completion date | August 31, 2019 |
| Est. primary completion date | September 25, 2018 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 50 Years to 75 Years |
| Eligibility | Inclusion Criteria: - Aged 50-75 - Self-identify as AI (from any tribe) - Are not up-to-date with recommended screening in accordance with USPSTF guidelines. Exclusion Criteria: - Patients who have a personal or family history of CRC or adenomatous polyps or inherited genetic conditions that increase CRC risk (familial adenomatous polyposis, Lynch syndrome, Turcot syndrome, Peutz-Jeghers syndrome, or MUTYH-associated polyposis) - Unable to speak English - Severe cognitive, visual, or hearing impairment that would prevent decision aid viewing. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Robeson Health Care Corporation | Lumberton | North Carolina |
| Lead Sponsor | Collaborator |
|---|---|
| UNC Lineberger Comprehensive Cancer Center |
United States,
Frerichs L, Beasley C, Pevia K, Lowery J, Ferrari R, Bell R, Reuland D. Testing a Culturally Adapted Colorectal Cancer Screening Decision Aid Among American Indians: Results from a Pre-Post Trial. Health Equity. 2020 Apr 1;4(1):91-98. doi: 10.1089/heq.201 — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | CRC screening intentions | Measure of screening intent from prior CRC screening decision aid studies and assessed using a single categorical item regarding intentions to get CRC screening with four response options. | Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey. | |
| Secondary | Knowledge | Assessed by a six-item index (based on decision aid content). Items include 1) the availability of more than one option for CRC screening; 2) the availability of a home screening test; 3) the recommended age to begin CRC screening; 4) FOBT screening test frequency; 5) the need for sedation (and companion driver) for colonoscopy procedure, and 6) the existence of a small but non-zero complication risk associated with having colonoscopy. | Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey. | |
| Secondary | Attitudes | Assesses attitudes about how important items are for a participant's decision of whether or not to get CRC screening, including potential pros (e.g., having peace of mind after receiving clear findings) and cons (e.g., being worried or concerned that if you do the test you might find something wrong) with 4-point Likert-scale response options. | Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey. | |
| Secondary | Perceived social norms | Assesses the participant's belief that family, friends, and doctors think he/she should be screened. | Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey. | |
| Secondary | Personal agency | Assesses confidence to complete screening with 4-point Likert-scale response options (i.e., not at all confident, not very confident, confident, very confident). | Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey. | |
| Secondary | CRC screening preferences | Measures screening preferences from prior studies. | Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey. | |
| Secondary | Healthcare provider communication | Assessed with a participant-reported measure of having had a CRC screening discussion with a healthcare provider in the prior 5 months based on items used in a national survey. | Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey. | |
| Secondary | Family and friend communication | Assessed using a measured adapted from a study on family communication about cancer screening. Participants asked to enumerate social network members and will be asked to identify members with whom they discussed CRC screening. | Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey. | |
| Secondary | CRC screening completion | Dichotomous indicator of whether or not the participant completed any of the recommended CRC screening tests. | Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |